info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Asia Pacific Lancet Pen Needels Market Size

ID: MRFR//0187-HCR | 90 Pages | Author: Kinjoll Dey| December 2024

The ASIA PACIFIC LANCET AND PEN NEEDLES market is significantly influenced by the growing diabetes epidemic in the region. With a substantial increase in the number of individuals diagnosed with diabetes, there is a corresponding surge in the demand for lancets and pen needles for blood glucose monitoring and insulin administration, driving market growth. The LANCET AND PEN NEEDLES market in Asia pacific is shaped by progress in technology. The continual innovation with respect to the design of both lancet and pen needles, which are related to finer sample gauges, painless injection mechanisms, and improved safety measures leads to positive patient experience and compliance with diabetes management protocols.
Though Asia Pacific on a continual basis experiences the developments in healthcare infrastructure, they are generally responsible for increased accessibility and utilization of diabetes management devices. The developments whereby, healthcare centers are being developed more often, especially in the global areas where economic growth is taking shape is also created a climate for uptake of lancets and pen needles into the clinical routine practice.
Injection therapies for diabetes treatment, with insulin pens being one of the most popular choices, determine the amount of needles that are needed for pens. Established by the growing popularity in injecting healthcare, the trend for congruent self- administering pen needles changes the dynamics in the market.
The emergence of patient driven healthcare and self-monitoring drives the demand for lancets and pen needles. The adoption of pen needles and lancets are increased in the Asia Pacific region due to the demand of convenient and user-friendly devices thus blood glucose monitoring and insulin administration.
Public health programs and government initiatives that focus on diabetes control stimulate market development. The establishment of programs for the prevention and control of diabetes drives the adoption of these lancets and pen needles through subisidjie s, awareness campaigns, and the programs themselves.
Healthcare spending alone is a vital factor affecting the LANCET AND PEN NEEDLES market, other factors are such as income revenue and insurance coverage. Economic stability and decided allocation of government budget on health care affects purchasing power of both purchasers and consumers.
However, cultural specification and population health consciousness is shaping up lancets and pen needles adoption. As health consciousness is growing, there is a trend that people are willing to spend money on devices which allow them to monitor their blood glucose and administer insulin more regularly because such cultural values dictate that they promote wellness.
There is a demographic shift towards an aging population in some Asia Pacific countries which contributes to the incidence of diabetes and the appetite for lancets and pen needles. The market for suitable products targeted for older adults is driven by the diabetes management devices necessary for the older adults.
Intense competition for key players in the LANCET AND PEN NEEDLES market in the Asia Pacific forces the brand differentiation. Market competitors try to gain advantage by creating unique and interesting properties, quality of manufactured products and establishing a brand loyalty.
The adoption of telehealth services and remote monitoring technologies in Asia Pacific influences the market. Remote monitoring capabilities in lancet and pen needle devices allow healthcare providers to track patient data and provide timely interventions, aligning with the growing trend of digital healthcare solutions.

Asia Pacific Lancet and Pen Needles Market Overview


Asia Pacific Lancet and Pen Needles Market Size was valued at USD 1.85 Billion in 2023. The Global Asia Pacific Lancet and Pen Needles industry is projected to grow from USD 1.95 Billion in 2024 to USD 3.45 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.67% during the forecast period (2024 - 2032).

Asia Pacific Lancet and Pen Needles Market

Lancet and pen needles can be effectively used for the blood-based diagnosis, monitoring, and medication of diseases like diabetes and osteoporosis.  Pen needles are used in conjunction with the injection pens. Structurally, a pen needle consists of a hollow needle, which is embedded in a plastic hub and attaches to the injection pen. The lancet are double edged blades or needles and appears similar to the small scalpels. 

The market for lancet and pen needles is expected to grow at a healthy CAGR during the forecast period in the Asia Pacific region due to increasing prevalence of diseases like diabetes and osteoporosis. According to a study conducted by the American Diabetes Association in 2016, about 80% of the diabetic patients resides in the developing countries and it is estimated that the rise of type 2 diabetes in South Asia is likely to be 150% between 2000 and 2035. Moreover, in the Western Pacific region, the number of diabetic patients is expected to reach 201.8 million by 2035. 

Additionally, according to the International Osteoporosis Foundation by 2050, over ~50% of all osteoporotic hip fractures are expected to occur in Asia. Factors such as increasing geriatric population and growing healthcare expenditure along with favourable government policies are projected to boost the market growth during the forecast period.  However, the need to remove the pin after a single use and high cost as compared to the insulin vials may restrain the market growth during the forecast period. 

Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers 


Asia Pacific Lancet and Pen Needles Market Segmentation


The Asia Pacific lancet and pen needles market is segmented on the basis of therapy, gauge, needle length, and end users.


On the basis of the therapy, the market is segmented into insulin, glucagon-like peptide-1 (GLP-1), growth hormones, and others.


On the basis of the gauge, the market is categorized into 17/18G, 21G, 23G, and others.


On the basis of the needle length, the market is segmented into 4mm, 8mm, 12mm, and others.


On the basis of the end users, the market is segmented into hospitals & clinics, medical institutions & research organizations, and others.


Asia Pacific Lancet and Pen Needles Market Regional Analysis


On the regional basis, Asia Pacific is segmented into Japan, India, China, the Republic of Korea, Australia, and the Rest of Asia Pacific.

Japan holds a major share of the market followed by the Republic of Korea and Australia owing to the well-developed healthcare sector and high per capita healthcare expenditure. In 2014, according to the Statistics Bureau, Japan’s total medical care expenditure was about 11.20% of the national income, which accounted for USD 0.37 trillion. Additionally, favorable governmental policies boost the market growth in these regions.

China and India have a growing market due to huge population base, increasing demand for the better quality products, rapidly changing the economy, increasing healthcare expenditure, and rising number of pharmaceutical & biotechnological companies. Moreover, increasing number of healthcare organizations like a hospital, the private research institute has led to increasing in the market in India. Rest of Asia Pacific holds the least share of the market.

Key Players for Asia Pacific Lancet and Pen Needles Market


Some of the key players in the Asia Pacific lancet and pen needles market are: 



  • BD. (U.S.)

  • Novo Nordisk A/S (Europe)

  • Ypsomed (Europe)

  • B. Braun Melsungen AG (Europe)

  • HTL-STREFA (Europe)

  • Terumo Corporation (Asia Pacific)

  • Artsana S.p.A. (Europe)

  • Owen Mumford Ltd. (Europe)


Recent Developments


February 2024: Eli Lilly hopes to launch its bestselling antidiabetic medication, specified as Mounjaro (tripeptide), which will be around early next year. Indian health regulatory bodies, including Mounjaro, are currently investigating this.


According to Minister Mykhailo Fedorov for Digital Transformation in Ukraine, contracts will be signed first about the mass production of attack drones similar to Russian Lancet drones in February 2024. Among them is the kamikaze drone Lancet manufactured by ZALA Aero Group, which has a range of forty kilometers and belongs to Kalashnikov Concern’s large enterprise division, Russian Armaments Manufacturer.


June 2023: Shilpa Biologicals Private Limited (SBPL), a wholly owned subsidiary of Shilpa Medicare Limited (SML), was granted marketing authorization for its Adalimumab injection in prefilled syringe (PFS). It is a biosimilar for high concentration adalimumab formulation for rheumatoid arthritis treatment.


During CPHI Japan 2023, SHL Medical introduced Molly modular platform autoinjectors with pre-installed Needle Isolation Technology (NIT).




September 2022: The Microsoft and Novo Nordisk partnership was announced in September 2022, merging computational services, cloud computing AI and knowledge thirst in drug development as well as Novo Nordisk’s data engineering services.


On September 2022, Novo Nordisk acquired Forma Therapeutics. That company is committed to changing lives of Sickle cell disease (SCD) patients among other rare blood diseases.


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.